Importantly, ferroptosis inducing agents are associated with overcoming chemoresistance as recent studies suggest that cancer cells resistant to typical apoptosis inducing molecules are highly dependent on GPX4 [54, 65], which could also potentially explain the successful outcome of volasertib in phase II of clinical trial on relapsed or refractory AML, but not on therapy-naive patients. The gene discussed is GPX4; the disease is cancer.